Champions Oncology, Inc. CSBR
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 36.13% | -96.76% | -226.97% | 157.30% | 74.60% |
| Total Depreciation and Amortization | -2.18% | -5.87% | -4.48% | -0.28% | -9.14% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 36.97% | -12.14% | 33.90% | 26.92% | -12.54% |
| Change in Net Operating Assets | 41.09% | -9.34% | 26.59% | -1,610.05% | -97.42% |
| Cash from Operations | 75.38% | -49.22% | 22.82% | -389.17% | -91.26% |
| Capital Expenditure | 76.99% | -545.95% | 84.71% | -426.09% | 81.82% |
| Sale of Property, Plant, and Equipment | -- | -95.65% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 76.89% | -1,600.00% | 94.21% | -426.09% | 81.82% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 51.28% | 0.00% | -2.63% | 0.00% |
| Issuance of Common Stock | -- | -100.00% | -98.55% | 762.50% | 300.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 273.68% | 47.22% | -121.43% | 1,300.00% | 56.25% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 77.21% | -62.35% | 23.22% | -435.00% | -91.80% |